After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4).
IOVA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Iovance Biotherapeutics Inc is $2.22B. A total of 6.15 million shares were traded on the day, compared to an average of 7.63M shares.
In the most recent transaction, MCPEAK MERRILL A bought 10,000 shares of IOVA for 5.56 per share on Sep 18. After the transaction, the Director now owns 248,633 company shares. In a previous transaction on Sep 15, Rothbaum Wayne P. bought 5,000,000 shares at 5.30 per share. IOVA shares that Director owns now total 23,067,333.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for IOVA in the last 3 months, the mean price target is $20.42 with high estimates of $30.00 and low estimates of $12.00. In terms of 52-week highs and lows, IOVA has a high of $10.31 and a low of $3.21.
As of this writing, IOVA has an earnings estimate of $Sunnova Energy International In per share for the current quarter. EPS was calculated based on a consensus of Iovance Biotherapeutics, Inc. estimates, with a high estimate of $Inventiva S.A. – American Depos per share and a lower estimate of $Innoviva, Inc.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. IOVA’s latest balance sheet shows that the firm has $504.41M in Cash & Short Term Investments as of fiscal 2021. There were $71.53M in debt and $89.20M in liabilities at the time. Its Book Value Per Share was $2.63, while its Total Shareholder’s Equity was $621.66M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IOVA is Buy with a score of 4.86.